Name: Johnson & Johnson Innovation
Start: 2020-09-29
End: 2020-09-30
Location: Digital Conference

Presenting new therapeutic solutions to a global audience

Our platform has too much potential to keep it secret. Which is why we publish, inform, and present. After all, you want to know where your future therapies are starting.

Press contact

eleva GmbH
Fabienne Zeitter
pr@elevabiologics.com
Phone: +49 761 470 99 0

Press contact

eleva GmbH
Fabienne Zeitter
pr@elevabiologics.com
Phone: +49 761 470 99 0

elevaFollow5882

eleva @elevabiologics·

2h 1311296789094465536

Only a few days after our 500l bioreactor has been restarted, it is time for the first sampling. During the next days our quality control team will measure the intracellular and extracellular product concentration to determine how much #FactorH the current run produces.

Reply on Twitter 1311296789094465536 Retweet on Twitter 1311296789094465536 Like on Twitter 1311296789094465536 Twitter 1311296789094465536

eleva @elevabiologics·

29 Sep 1310921762939580416

Do not miss our online presentation tomorrow at 15:00 CET! Our Director Business Development Jana Gross will participate in the @JNJNews Innovation Event "Next Wave in Immune Therapeutics" and tell you why our technology is the key to the therapies of the future. #elevabiologics

Reply on Twitter 1310921762939580416 Retweet on Twitter 13109217629395804161 Like on Twitter 13109217629395804164 Twitter 1310921762939580416

eleva @elevabiologics·

17 Sep 1306485427986214913

Assets, platform, company and a lot more! Our brand new website has just gone online. Take a look at our pipeline and learn how we at #eleva are using our unique production platform to pave the way to new and better #therapies.
https://t.co/WaR0ZVtCy5

Reply on Twitter 1306485427986214913 Retweet on Twitter 13064854279862149131 Like on Twitter 13064854279862149133 Twitter 1306485427986214913

eleva @elevabiologics·

14 Sep 1305416730727116800

Don't miss the opportunity to learn all about #eleva from 21-24 September at the upcoming Biotech in Europe Forum!
#elevabiologics #noveltherapeutics #clinicalassets https://t.co/GlSHewWnoE

Reply on Twitter 1305416730727116800 Retweet on Twitter 13054167307271168001 Like on Twitter 13054167307271168003 Twitter 1305416730727116800

eleva @elevabiologics·

31 Aug 1300383149764104192

Welcome back home! For six months we produced our recombinant Factor H under GMP conditions in the cleanroom of Bibitec in Bielefeld. Since today, our 500l reactor for industrial scale production is again available to our R&D team at the Freiburg site.
#elevabiologics #GMP

Reply on Twitter 1300383149764104192 Retweet on Twitter 1300383149764104192 Like on Twitter 13003831497641041923 Twitter 1300383149764104192

Press releases

Greenovation transforms into Eleva

May 18, 2020

Greenovation is launching its supreme moss-based development platform with a new business model and is transforming into a new company, Eleva.

Eleva’s drug candidate to be examined for use in Covid-19 treatment

June 3, 2020

Eleva, a manufacturer of superior biologics, is exploring the potential of one of its drug candidates for first-in-line therapy of Covid-19. The compound, factor H, is part of the complement system, which is believed to affect the severity of the course of Covid-19. Eleva has developed factor H previously for a different indication and taken it through pre-clinical stages.

Meet us here

Sep 29 2020 - Sep 30 2020

Johnson & Johnson Innovation

Digital Conference

Oct 05 2020 - Oct 06 2020

Health Tech Innovation Days

Paris, France

Oct 08 2020

Biovalley Companies Day

Freiburg, Germany

No event found!

In the press

Eleva entwickelt mit Geld aus Heilbronn Covid-19-Wirkstoff

June 18, 2020

Stimme.de – Unterstützt vom Zukunftsfonds Heilbronn entwickelt die Biotech-Firma Eleva einen Wirkstoff, der bei Covid-19-Patienten zum Einsatz kommen könnte. Gezüchtet wird er in Moos.

Read Article

Press kit

For non-commercial purposes only. Please only use the material in combination with Eleva GmbH copyright label.

Boilerplate

Based in Freiburg, Germany, Eleva develops novel biological therapies with its pharmaceutical partners. The privately-held company leverages its unique moss-based production platform to produce supreme biologics like antibodies, replacement enzymes, or fusion toxins. Eleva has successfully developed drug candidates into clinical phases.

Presenting new therapeutic solutions to a global audience

Press contact

News

Press contact

Press releases

Meet us here

In the press

Press kit

Boilerplate

eleva GmbH

eleva Newsletter